SPBC19G7.10c Antibody

What is SPBC19G7.10c and what cellular functions does it perform?

SPBC19G7.10c encodes the DNA topoisomerase 2-associated protein pat1 in Schizosaccharomyces pombe (fission yeast). This multifunctional protein primarily serves as a decapping activator and translational repressor pat1 . The protein is involved in several critical cellular processes including:

• Regulation of mRNA stability through its role in decapping complexes

• Translational repression during cellular stress responses

• Association with topoisomerase II, suggesting potential roles in DNA topology regulation

• Control of mRNA turnover pathways

Understanding pat1's function requires robust detection methods, with antibodies serving as primary research tools for characterizing its expression, localization, and interactions.

What validation methods provide the highest confidence for SPBC19G7.10c antibody specificity?

Genetic validation approaches using knockout controls provide significantly higher confidence than orthogonal methods for confirming antibody specificity. According to comprehensive antibody validation studies, antibodies validated using knockout methodology show substantially higher confirmation rates (89% for Western blot) compared to those validated using orthogonal approaches (80% for Western blot) .

For SPBC19G7.10c antibody validation, the recommended approach includes:

• Generate S. pombe SPBC19G7.10c knockout strain using CRISPR/Cas9

• Prepare protein extracts from wild-type and knockout strains

• Perform Western blot with SPBC19G7.10c antibody

• Confirm specificity through absence of signal in knockout samples

What are the primary applications for SPBC19G7.10c antibodies in yeast research?

SPBC19G7.10c antibodies enable multiple experimental approaches in fission yeast research:

• Western Blot (WB): Detection and quantification of pat1 protein expression levels under various conditions

• Enzyme-Linked Immunosorbent Assay (ELISA): Quantitative measurement of pat1 protein levels

• Immunoprecipitation (IP): Isolation of pat1-containing protein complexes

• Immunofluorescence (IF): Visualization of subcellular localization patterns

• Chromatin Immunoprecipitation (ChIP): Investigation of potential DNA interactions through topoisomerase II association

Commercial polyclonal antibodies against SPBC19G7.10c are typically purified using antigen-affinity methods and are provided as IgG isotype preparations .

How should researchers design controls for SPBC19G7.10c antibody Western blot experiments?

Robust experimental design requires multiple controls to ensure reliable results with SPBC19G7.10c antibody:

Essential Controls:

• Genetic Negative Control:

  • Protein extract from SPBC19G7.10c knockout strain

  • Confirms specificity and identifies non-specific binding

• Positive Control:

  • Recombinant SPBC19G7.10c protein or extract from cells overexpressing the protein

  • Verifies antibody functionality and target recognition

• Loading Control:

  • Detection of housekeeping protein (e.g., actin) across all samples

  • Ensures equal protein loading and transfer

• Secondary Antibody-Only Control:

  • Omission of primary antibody

  • Identifies non-specific secondary antibody binding

• Peptide Competition Control:

  • Pre-incubation of antibody with immunizing peptide

  • Should eliminate specific signal if antibody is properly targeted

Research shows that genetic controls using knockout methodology provide the highest validation confidence, with 89% of antibodies recommended for Western blot applications confirmed using this approach .

What optimization strategies improve SPBC19G7.10c antibody performance in immunofluorescence?

Immunofluorescence applications with SPBC19G7.10c antibody require careful optimization due to the higher false-positive rates observed with this technique. Studies demonstrate that only 38% of antibodies validated by orthogonal approaches for immunofluorescence were confirmed using knockout controls .

Step-wise Optimization Protocol:

• Fixation Method Testing:

  • Compare 4% paraformaldehyde (15 min) vs. methanol fixation (-20°C, 10 min)

  • Evaluate combination protocols (PFA followed by methanol)

• Permeabilization Optimization:

  • Test detergent gradients: 0.1-0.5% Triton X-100

  • Compare with alternative agents: 0.05-0.25% Saponin

  • Optimize duration: 5-15 minutes

• Antibody Dilution Matrix:

  • Primary antibody: Test range from 1:50 to 1:500

  • Secondary antibody: Evaluate 1:200 to 1:1000

  • Include concentration gradient to determine optimal signal-to-noise ratio

• Essential Validation Controls:

  • SPBC19G7.10c knockout strain (signal should be absent)

  • Peptide competition (pre-incubation with immunizing peptide)

  • Secondary-only control (omit primary antibody)

Pat1 protein typically displays cytoplasmic localization with potential concentration in RNA processing bodies under certain conditions, with possible nuclear localization reflecting its topoisomerase II association.

How can computational approaches enhance SPBC19G7.10c antibody design and specificity?

Computational methodologies offer significant advantages for antibody design and optimization, potentially improving SPBC19G7.10c antibody performance:

• Epitope Prediction and Analysis:

  • Identify unique regions of SPBC19G7.10c not present in related proteins

  • Predict surface-exposed epitopes with higher accessibility

  • Exclude regions with cross-reactivity potential

• Structural Modeling and Docking:

  • Apply RosettaAntibody for 3D structure prediction of potential antibodies

  • Implement two-step docking approach using ClusPro (global docking) followed by SnugDock (local refinement)

  • Predict antibody-antigen binding poses to optimize recognition

• Computational Affinity Maturation:

  • Perform in silico mutation analysis of antibody variable regions

  • Identify mutations that enhance specificity for SPBC19G7.10c

  • Design improved antibody candidates with reduced cross-reactivity

The IsAb computational antibody design protocol provides a structured approach:

• Generate 3D models using Rosetta when structural information is unavailable

• Conduct energy minimization to optimize conformations

• Perform global and local docking simulations

• Identify interaction hotspots through alanine scanning

• Implement computational affinity maturation to enhance binding properties

How can SPBC19G7.10c antibody be used to investigate mRNA decapping mechanisms?

SPBC19G7.10c antibody enables multiple approaches for investigating pat1's role in mRNA decapping and translational repression:

Methodological Approaches:

• Co-Immunoprecipitation (Co-IP) Studies:

  • Immunoprecipitate pat1 complexes using SPBC19G7.10c antibody

  • Identify associated decapping factors (Dcp1, Dcp2) and translational regulators

  • Protocol optimization:

    • Cross-linking with formaldehyde preserves transient interactions

    • RNase treatment distinguishes RNA-dependent vs. direct protein interactions

• RNA-Immunoprecipitation (RIP):

  • Identify mRNAs directly bound by pat1 protein

  • Compare bound transcriptome profiles under normal vs. stress conditions

  • Analyze RNA features contributing to pat1 recognition

• Functional Complementation Studies:

  • Express epitope-tagged variants of pat1 in knockout strains

  • Use SPBC19G7.10c antibody to confirm expression levels

  • Assess restoration of decapping activity and translational regulation

For co-immunoprecipitation experiments, optimization of extraction conditions is critical, as different buffer compositions can significantly affect the stability of protein complexes and antibody recognition efficiency.

What considerations are important when using SPBC19G7.10c antibody for studying pat1-topoisomerase II interactions?

Investigating pat1's association with topoisomerase II requires careful experimental design considerations:

Critical Experimental Parameters:

• Nuclear Extraction Optimization:

  • Standard lysis buffers may be insufficient for nuclear proteins

  • Test nuclear extraction protocols with increasing salt concentrations (150mM, 300mM, 450mM NaCl)

  • Include phosphatase inhibitors to preserve interaction-relevant modifications

• Cross-linking Considerations:

  • Protein-DNA-protein complexes may require specialized cross-linking

  • Compare formaldehyde (protein-DNA) with protein-specific cross-linkers (DSP, BS3)

  • Optimize cross-linking duration to preserve interactions without over-fixation

• Reciprocal Co-IP Validation:

  • Perform IP with SPBC19G7.10c antibody, detect topoisomerase II

  • Conduct reciprocal IP with topoisomerase II antibody, detect pat1

  • Agreement between approaches strengthens interaction evidence

• Functional Correlation Studies:

  • Assess topoisomerase II enzymatic activity in presence/absence of pat1

  • Investigate how pat1 mutations affect interaction with topoisomerase II

  • Evaluate co-localization during different cell cycle phases

Correlating biochemical interaction data with functional outcomes provides more compelling evidence for biologically significant associations between pat1 and topoisomerase II.

How should researchers analyze cross-reactivity of SPBC19G7.10c antibody with related proteins?

Comprehensive cross-reactivity analysis ensures experimental reliability and prevents misinterpretation of results:

Cross-Reactivity Assessment Framework:

• Sequence Homology Analysis:

  • Identify proteins with sequence similarity to SPBC19G7.10c/pat1

  • Focus particularly on the epitope region recognized by the antibody

  • Create homology map of related proteins across species:

  Protein	Species	% Identity to Epitope Region	Cross-Reactivity Risk
  Pat1 homolog	S. cerevisiae	[value]	[High/Medium/Low]
  Pat1B	Human	[value]	[High/Medium/Low]
  Related RNA-binding proteins	S. pombe	[value]	[High/Medium/Low]

• Experimental Cross-Reactivity Testing:

  • Test antibody reactivity against recombinant related proteins

  • Examine extracts from different species expressing pat1 homologs

  • Use epitope-tagged versions of related proteins as positive controls

• Advanced Validation Methods:

  • Epitope Mapping: Determine precise antibody recognition site

  • Immunodepletion: Sequentially deplete lysates of related proteins

  • Mass Spectrometry: Identify all proteins captured by immunoprecipitation

Studies show that many commercial antibodies do not recognize their intended targets with perfect specificity , highlighting the importance of rigorous cross-reactivity testing, particularly when studying conserved proteins like pat1 that share domains with related protein family members.

What are common issues with SPBC19G7.10c antibody in Western blot and how can they be resolved?

Researchers frequently encounter several challenges when using SPBC19G7.10c antibody in Western blot applications:

Issue 1: Weak or No Signal

Issue 2: High Background or Multiple Bands

How can researchers troubleshoot SPBC19G7.10c antibody specificity concerns in their experiments?

When specificity concerns arise with SPBC19G7.10c antibody, a systematic troubleshooting approach is required:

Step 1: Control-Based Assessment

• Compare signal between wild-type and SPBC19G7.10c knockout samples

• If signal persists in knockout, antibody exhibits non-specific binding

• Analyze pattern: diffuse background vs. distinct bands suggests different issues

Step 2: Epitope Analysis

• Perform epitope mapping to identify exact recognition sequence

• Compare with similar sequences in proteome to identify potential cross-reactants

• Consider epitope masking by protein modifications or interactions

Step 3: Validation Through Multiple Methods

• Compare results across multiple applications (WB, IP, IF)

• Disagreement between methods suggests application-specific issues

• Consistent patterns across methods strengthen confidence in observations

Step 4: Alternative Antibody Comparison

• Test multiple antibodies targeting different epitopes of SPBC19G7.10c

• Agreement between independent antibodies increases confidence

• Discrepancies highlight potential epitope-specific limitations

Research indicates that many antibodies fail validation in at least one application, with immunofluorescence showing particularly high failure rates (62% of antibodies validated by orthogonal methods failed knockout validation) .

What methodological approaches can improve reproducibility when working with SPBC19G7.10c antibody?

Enhancing experimental reproducibility with SPBC19G7.10c antibody requires standardization across multiple parameters:

Standardization Framework:

• Antibody Handling and Storage:

  • Aliquot antibody upon receipt to minimize freeze-thaw cycles

  • Document lot numbers and maintain consistent supplier

  • Store according to manufacturer recommendations (typically -20°C)

• Sample Preparation Consistency:

  • Standardize cell growth conditions (medium, density, harvest phase)

  • Use consistent lysis buffer composition and protein extraction protocol

  • Quantify protein concentration using reliable method (BCA or Bradford)

• Experimental Controls Integration:

  • Include genetic controls (knockout) in every experiment

  • Use consistent positive controls (recombinant protein or overexpression)

  • Implement loading controls appropriate for experimental conditions

• Protocol Documentation and Validation:

  • Maintain detailed protocol records including all reagent information

  • Validate each new antibody lot against previous results

  • Document optimization parameters that improved performance

Studies of antibody validation methods demonstrate that rigorous documentation and standardization significantly improve reproducibility, with genetic controls providing the highest confidence in specificity across experimental approaches .